Sloning BioTechnology Starting Feasibility Study for bioMerieux
News Aug 17, 2007
Sloning BioTechnology GmbH, provider of gene mutant libraries (SlonoMax™), will carry out a feasibility study together with bioMerieux. The aim of the project is to generate a large number of different gene variants of an essential enzyme to be used in diagnostic applications.
Sloning will use its Slonomics™ industrial scale gene synthesis technology to provide a gene library with a full set of ratio-controlled mutants. The successful completion of the study will enable bioMerieux to identify an enzyme with significantly enhanced characteristics.
“We are very excited about this collaboration. It gives Sloning the opportunity to demonstrate the capabilities of our enabling technology in the field of protein engineering and synthetic biology and in this particular case with a significant commercial impact to our customer.” stated Dr. Heinz Schwer, the company CEO.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.